Nuvalent (NUVL) Change in Account Payables (2020 - 2026)
Nuvalent (NUVL) reported Change in Account Payables of -$7.7 million for Q1 2026, down 136.71% on a YoY basis from $20.9 million in Q1 2025, and down 198.39% quarter-over-quarter from $7.8 million in Q4 2025.
Nuvalent (NUVL) Change in Account Payables (2020 - 2026) Analysis & Trends
Nuvalent has reported Change in Account Payables for 7 years, with the latest figure at -$7.7 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 136.71% year-over-year to -$7.7 million; the trailing twelve-month figure through Mar 2026 stood at -$4.0 million (down 131.55% YoY), and the FY2025 full-year result was $24.6 million, up 707.53% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$7.7 million, down from $7.8 million in the prior quarter.
- The five-year high for Change in Account Payables was $20.9 million in Q1 2025, with the low at -$12.8 million in Q2 2025.
- Historically, Change in Account Payables has averaged $1.1 million across 5 years, with a median of $1.4 million in 2022.
- Annual changes were most pronounced in 2023 — Change in Account Payables jumped 872.48% — and 2024, when it slumped 1996.45%.
- Nuvalent's Change in Account Payables stood at $2.5 million in 2022, then tumbled by 120.4% to -$507000.0 in 2023, then tumbled by 1996.45% to -$10.6 million in 2024, then soared by 173.52% to $7.8 million in 2025, then tumbled by 198.39% to -$7.7 million in 2026.
- The last three Change in Account Payables figures came in at -$7.7 million (Q1 2026), $7.8 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -9.42 Mn |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | -7.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.69 Mn |
| Mar 31, 2026 | -7.69 Mn |
| Dec 31, 2025 | 7.81 Mn |
| Dec 31, 2025 | 7.81 Mn |
| Sep 30, 2025 | 8.67 Mn |
| Sep 30, 2025 | 8.67 Mn |
| Jun 30, 2025 | -12.82 Mn |
| Jun 30, 2025 | -12.82 Mn |
| Mar 31, 2025 | 20.94 Mn |
| Mar 31, 2025 | 20.94 Mn |
| Dec 31, 2024 | -10.63 Mn |
| Dec 31, 2024 | -10.63 Mn |
| Sep 30, 2024 | 8.45 Mn |
| Sep 30, 2024 | 8.45 Mn |
| Jun 30, 2024 | -5.99 Mn |
| Jun 30, 2024 | -5.99 Mn |
| Mar 31, 2024 | 4.12 Mn |
| Mar 31, 2024 | 4.12 Mn |
| Dec 31, 2023 | -507,000.00 |
| Dec 31, 2023 | -507,000.00 |